Xeris Biopharma climbs on research collaboration with Regeneron

Xeris Biopharma Holdings

30/03/2023 12:38

** Xeris Biopharma Holdings Inc's  XERS.O  shares rise 11.4%
to $1.47 premarket 
    ** Drug developer enters research evaluation collaboration
and option agreement with Regeneron Pharmaceuticals Inc  REGN.O 
    ** XERS will use its drug delivery system, XeriJect, to
develop concentrated small volume subcutaneous injections of two
undisclosed monoclonal antibodies developed by REGN, according
to the agreement
    ** Without disclosing financial details about the deal,
Xeris said it will receive an upfront payment and potential
milestone payments for pre-clinical achievements
    ** REGN also has an option to commercially license XERS's
technology under the deal
    ** As of last close, XERS shares down ~1% YTD

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com))